Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones. The condition often results in end stage renal disease (ESRD), which is a life-threatening condition that prevents the kidneys from filtering fluids and waste products from the body effectively.
Mutations in the AGXT, GRHPR, and HOGA1 genes cause primary hyperoxaluria types 1, 2, and 3, respectively. These genes provide instructions for making enzymes that are involved in the breakdown and processing of protein building blocks (amino acids) and other compounds. The enzyme produced from the HOGA1 gene is involved in the breakdown of an amino acid, which results in the formation of a compound called glyoxylate. This compound is further broken down by the enzymes produced from the AGXT and GRHPR genes.
Primary hyperoxaluria is estimated to affect 1 in 58,000 individuals worldwide. Type 1 is the most common form, accounting for approximately 80 percent of cases. Types 2 and 3 each account for about 10 percent of cases.
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
Dawn Milliner is a Nephrologist in Rochester, Minnesota. Milliner has been practicing medicine for over 47 years and is rated as an Elite expert by MediFind in the treatment of Primary Hyperoxaluria. She is also highly rated in 13 other conditions, according to our data. Her top areas of expertise are Primary Hyperoxaluria, Primary Hyperoxaluria Type 2, Nephrocalcinosis, Kidney Transplant, and Endoscopy. She is licensed to treat patients in Minnesota.
Bernd Hoppe practices in Bonn, Germany. Hoppe is rated as an Elite expert by MediFind in the treatment of Primary Hyperoxaluria. He is also highly rated in 26 other conditions, according to our data. His top areas of expertise are Primary Hyperoxaluria, Nephrocalcinosis, Primary Hyperoxaluria Type 1, Kidney Transplant, and Liver Transplant.
John Lieske is a Nephrologist in Rochester, Minnesota. Lieske has been practicing medicine for over 37 years and is rated as an Elite expert by MediFind in the treatment of Primary Hyperoxaluria. He is also highly rated in 24 other conditions, according to our data. His top areas of expertise are Kidney Stones, Primary Hyperoxaluria, Dent Disease, Kidney Transplant, and Gastric Bypass. He is licensed to treat patients in Minnesota. Lieske is currently accepting new patients.
Summary: The purpose of this study is to evaluate the long-term safety and tolerability of lumasiran in patients with Primary Hyperoxaluria Type 1.
Summary: The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).
Published Date: December 01, 2015Published By: National Institutes of Health